NO318464B1 - Nye kamptotekinanaloge forbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem - Google Patents
Nye kamptotekinanaloge forbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem Download PDFInfo
- Publication number
- NO318464B1 NO318464B1 NO20005807A NO20005807A NO318464B1 NO 318464 B1 NO318464 B1 NO 318464B1 NO 20005807 A NO20005807 A NO 20005807A NO 20005807 A NO20005807 A NO 20005807A NO 318464 B1 NO318464 B1 NO 318464B1
- Authority
- NO
- Norway
- Prior art keywords
- formula
- group
- compounds
- alkyl
- groups
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- 150000001875 compounds Chemical class 0.000 title claims description 89
- 238000000034 method Methods 0.000 title claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 24
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 239000002253 acid Substances 0.000 claims abstract description 15
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 14
- -1 diastereoisomers Chemical class 0.000 claims abstract description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 5
- 125000000466 oxiranyl group Chemical group 0.000 claims abstract description 5
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims abstract description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims abstract description 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 21
- 239000007858 starting material Substances 0.000 claims description 19
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 125000004043 oxo group Chemical group O=* 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 150000002941 palladium compounds Chemical class 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910003827 NRaRb Inorganic materials 0.000 abstract description 4
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract description 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 3
- 125000003107 substituted aryl group Chemical group 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 99
- 239000000047 product Substances 0.000 description 56
- 239000000243 solution Substances 0.000 description 56
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 37
- 239000000203 mixture Substances 0.000 description 34
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 26
- 239000011541 reaction mixture Substances 0.000 description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- 239000003480 eluent Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 238000004587 chromatography analysis Methods 0.000 description 19
- 239000012074 organic phase Substances 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 15
- 235000019341 magnesium sulphate Nutrition 0.000 description 15
- 239000000377 silicon dioxide Substances 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 238000001819 mass spectrum Methods 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- KGDFHGMTFPQPSG-UHFFFAOYSA-N 2-bromo-3-(bromomethyl)quinoline Chemical compound C1=CC=C2N=C(Br)C(CBr)=CC2=C1 KGDFHGMTFPQPSG-UHFFFAOYSA-N 0.000 description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 4
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 150000002596 lactones Chemical group 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- IFXZQSXMHWZLKA-UHFFFAOYSA-N 2-bromo-3-(bromomethyl)-6,7-difluoroquinoline Chemical compound BrCC1=C(Br)N=C2C=C(F)C(F)=CC2=C1 IFXZQSXMHWZLKA-UHFFFAOYSA-N 0.000 description 2
- VONGIOGTLFSXDE-UHFFFAOYSA-N 2-fluoro-4-iodopyridine-3-carbaldehyde Chemical compound FC1=NC=CC(I)=C1C=O VONGIOGTLFSXDE-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- XPIWVCAMONZQCP-UHFFFAOYSA-N methyl 2-oxobutanoate Chemical compound CCC(=O)C(=O)OC XPIWVCAMONZQCP-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- WLXBKSLBVJYMLS-HTLJXXAVSA-N (5s)-5-ethyl-1-fluoro-6,7-dihydrocyclopenta[c]pyridine-5,6-diol Chemical compound C1=CN=C(F)C2=C1[C@](CC)(O)C(O)C2 WLXBKSLBVJYMLS-HTLJXXAVSA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N 1-propanol Substances CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- PHGLYQGVAGLHTN-UHFFFAOYSA-N 2-(triphenyl-$l^{5}-phosphanylidene)acetic acid Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)O)C1=CC=CC=C1 PHGLYQGVAGLHTN-UHFFFAOYSA-N 0.000 description 1
- BSDMDKVEIUWXER-UHFFFAOYSA-N 2-[(2-bromoquinolin-3-yl)methyl]-7-hydroxy-6,7-dihydrocyclopenta[c]pyridine-1,5-dione Chemical compound C1=CC=C2N=C(Br)C(CN3C=CC=4C(=O)CC(C=4C3=O)O)=CC2=C1 BSDMDKVEIUWXER-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- PBVUFSYJMFPBMI-UHFFFAOYSA-N 2-bromo-3-(bromomethyl)-6,7-dimethylquinoline Chemical compound BrCC1=C(Br)N=C2C=C(C)C(C)=CC2=C1 PBVUFSYJMFPBMI-UHFFFAOYSA-N 0.000 description 1
- FKGAGJIRXRQHSK-UHFFFAOYSA-N 2-bromo-3-(bromomethyl)-6-chloroquinoline Chemical compound N1=C(Br)C(CBr)=CC2=CC(Cl)=CC=C21 FKGAGJIRXRQHSK-UHFFFAOYSA-N 0.000 description 1
- VSIUUBKHWAOYIC-UHFFFAOYSA-N 2-bromo-3-(bromomethyl)-6-methoxyquinoline Chemical compound N1=C(Br)C(CBr)=CC2=CC(OC)=CC=C21 VSIUUBKHWAOYIC-UHFFFAOYSA-N 0.000 description 1
- RUQGVIOLBPFHOP-UHFFFAOYSA-N 2-bromo-3-(bromomethyl)-7-chloro-6-methylquinoline Chemical compound BrCC1=C(Br)N=C2C=C(Cl)C(C)=CC2=C1 RUQGVIOLBPFHOP-UHFFFAOYSA-N 0.000 description 1
- XWSVFBVCHYQCLO-UHFFFAOYSA-N 2-fluoro-4-iodo-3-methylpyridine Chemical compound CC1=C(I)C=CN=C1F XWSVFBVCHYQCLO-UHFFFAOYSA-N 0.000 description 1
- FRJNAQONKJGNET-UHFFFAOYSA-N 2-fluoro-4-iodo-3-prop-2-enylpyridine Chemical compound FC1=NC=CC(I)=C1CC=C FRJNAQONKJGNET-UHFFFAOYSA-N 0.000 description 1
- XRTISYRXTFJCCB-UHFFFAOYSA-N 3-(1,3-dioxolan-2-yl)-2-fluoro-4-iodopyridine Chemical compound FC1=NC=CC(I)=C1C1OCCO1 XRTISYRXTFJCCB-UHFFFAOYSA-N 0.000 description 1
- BXYZFBZFOPCYGD-UHFFFAOYSA-N 3-[[3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy]methyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(COC=2C=C(C=CC=2)C=2C3=CC=CC(=C3N=CC=2C(=O)C=2C=CC=CC=2)C(F)(F)F)=C1 BXYZFBZFOPCYGD-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- GLWPNXWVGVWNIQ-UHFFFAOYSA-N 4-(1-ethoxyethenyl)-2-fluoropyridine-3-carbaldehyde Chemical compound CCOC(=C)C1=CC=NC(F)=C1C=O GLWPNXWVGVWNIQ-UHFFFAOYSA-N 0.000 description 1
- XAVGXAIHIMLASJ-UHFFFAOYSA-N 5-ethyl-1-fluoro-1,2,6,7-tetrahydrocyclopenta[c]pyridine-5,7-diol Chemical compound C1=CNC(F)C2=C1C(CC)(O)CC2O XAVGXAIHIMLASJ-UHFFFAOYSA-N 0.000 description 1
- BUZUSINGYUABQT-UHFFFAOYSA-N 5-ethyl-1-fluoro-7h-cyclopenta[c]pyridine Chemical compound C1=CN=C(F)C2=C1C(CC)=CC2 BUZUSINGYUABQT-UHFFFAOYSA-N 0.000 description 1
- TWZOQCGDLMDMMU-UHFFFAOYSA-N 5-ethyl-1-fluoro-8h-isoquinolin-5-ol Chemical compound N1=CC=C2C(CC)(O)C=CCC2=C1F TWZOQCGDLMDMMU-UHFFFAOYSA-N 0.000 description 1
- RLGCUQHIFQCOAR-UHFFFAOYSA-N 5-ethyl-5,7-dihydroxy-6,7-dihydro-2h-cyclopenta[c]pyridin-1-one Chemical compound C1=CNC(=O)C2=C1C(CC)(O)CC2O RLGCUQHIFQCOAR-UHFFFAOYSA-N 0.000 description 1
- PKRNJFOGKJWXRS-UHFFFAOYSA-N 5-ethyl-5-hydroxy-2,6-dihydrocyclopenta[c]pyridine-1,7-dione Chemical compound C1=CNC(=O)C2=C1C(CC)(O)CC2=O PKRNJFOGKJWXRS-UHFFFAOYSA-N 0.000 description 1
- TVKJWORHZPZPKV-UHFFFAOYSA-N 5-ethyl-5-hydroxy-7-methoxy-6,7-dihydro-2h-cyclopenta[c]pyridin-1-one Chemical compound C1=CNC(=O)C2=C1C(CC)(O)CC2OC TVKJWORHZPZPKV-UHFFFAOYSA-N 0.000 description 1
- GLMJLVBTEHEAMB-UHFFFAOYSA-N 6-bromo-7-(bromomethyl)-[1,3]dioxolo[4,5-g]quinoline Chemical compound C1=C2N=C(Br)C(CBr)=CC2=CC2=C1OCO2 GLMJLVBTEHEAMB-UHFFFAOYSA-N 0.000 description 1
- HBMOUOBIBYBIPK-UHFFFAOYSA-N 7-hydroxy-6,7-dihydro-2h-cyclopenta[c]pyridine-1,5-dione Chemical compound C1=CNC(=O)C2=C1C(=O)CC2O HBMOUOBIBYBIPK-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- CAHQGWAXKLQREW-UHFFFAOYSA-N Benzal chloride Chemical compound ClC(Cl)C1=CC=CC=C1 CAHQGWAXKLQREW-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000759909 Camptotheca Species 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000007093 Leukemia L1210 Diseases 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 101000924984 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) 3-dehydroquinate dehydratase Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- WMEDPYWNFHPWBH-UHFFFAOYSA-N chembl316118 Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)CC(=O)C5(O)CC)C4=NC2=C1 WMEDPYWNFHPWBH-UHFFFAOYSA-N 0.000 description 1
- CEXHYAFUVODQOF-UHFFFAOYSA-N chembl327547 Chemical compound FC1=C(F)C=C2C=C(CN3C4=CC5=C(C3=O)CC(=O)C5(O)CC)C4=NC2=C1 CEXHYAFUVODQOF-UHFFFAOYSA-N 0.000 description 1
- XAQKCDAFPAOWPB-UHFFFAOYSA-N chembl327813 Chemical compound C1=C(OC)C=C2C=C(CN3C4=CC5=C(C3=O)CC(=O)C5(O)CC)C4=NC2=C1 XAQKCDAFPAOWPB-UHFFFAOYSA-N 0.000 description 1
- NARVEOXKUHYBBS-UHFFFAOYSA-N chembl92201 Chemical compound C1=C(Cl)C=C2C=C(CN3C4=CC5=C(C3=O)CC(=O)C5(O)CC)C4=NC2=C1 NARVEOXKUHYBBS-UHFFFAOYSA-N 0.000 description 1
- NNFRIADVLHUVES-UHFFFAOYSA-N chembl93588 Chemical compound CC1=C(C)C=C2C=C(CN3C4=CC5=C(C3=O)CC(=O)C5(O)CC)C4=NC2=C1 NNFRIADVLHUVES-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 150000003997 cyclic ketones Chemical group 0.000 description 1
- ZLYYBDPDHSCVDU-UHFFFAOYSA-N cyclopenta[c]pyridin-6-one Chemical compound C1=CN=CC2=CC(=O)C=C21 ZLYYBDPDHSCVDU-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- LJOQGZACKSYWCH-UHFFFAOYSA-N dihydro quinine Natural products C1=C(OC)C=C2C(C(O)C3CC4CCN3CC4CC)=CC=NC2=C1 LJOQGZACKSYWCH-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- DGODWNOPHMXOTR-UHFFFAOYSA-N dipotassium;dioxido(dioxo)osmium;dihydrate Chemical compound O.O.[K+].[K+].[O-][Os]([O-])(=O)=O DGODWNOPHMXOTR-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 150000001261 hydroxy acids Chemical group 0.000 description 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical compound C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- KYXKFTNQVQTYCO-UHFFFAOYSA-N methyl 2-(2-fluoro-3-formylpyridin-4-yl)-2-phenylmethoxybutanoate Chemical compound C=1C=NC(F)=C(C=O)C=1C(CC)(C(=O)OC)OCC1=CC=CC=C1 KYXKFTNQVQTYCO-UHFFFAOYSA-N 0.000 description 1
- SPRDFQFZPNXHCX-UHFFFAOYSA-N methyl 2-(2-fluoro-3-methylpyridin-4-yl)-2-(methoxymethoxy)butanoate Chemical compound COCOC(CC)(C(=O)OC)C1=CC=NC(F)=C1C SPRDFQFZPNXHCX-UHFFFAOYSA-N 0.000 description 1
- YHPHNGGWPOGUPY-UHFFFAOYSA-N methyl 2-(2-fluoro-3-methylpyridin-4-yl)-2-hydroxybutanoate Chemical compound COC(=O)C(O)(CC)C1=CC=NC(F)=C1C YHPHNGGWPOGUPY-UHFFFAOYSA-N 0.000 description 1
- VYCBZJQDMNEORX-UHFFFAOYSA-N methyl 2-[3-(1,3-dioxolan-2-yl)-2-fluoropyridin-4-yl]-2-hydroxybutanoate Chemical compound COC(=O)C(O)(CC)C1=CC=NC(F)=C1C1OCCO1 VYCBZJQDMNEORX-UHFFFAOYSA-N 0.000 description 1
- XYIDEFTUQYLPGW-UHFFFAOYSA-N methyl 2-[3-(1,3-dioxolan-2-yl)-2-fluoropyridin-4-yl]-2-phenylmethoxybutanoate Chemical compound C=1C=NC(F)=C(C2OCCO2)C=1C(CC)(C(=O)OC)OCC1=CC=CC=C1 XYIDEFTUQYLPGW-UHFFFAOYSA-N 0.000 description 1
- QZHRNDVEVFHYFS-UHFFFAOYSA-N methyl 2-[3-(3-methoxy-3-oxopropyl)-2-oxo-1h-pyridin-4-yl]-2-phenylmethoxybutanoate Chemical compound C1=CNC(=O)C(CCC(=O)OC)=C1C(CC)(C(=O)OC)OCC1=CC=CC=C1 QZHRNDVEVFHYFS-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- DFNPRTKVCGZMMC-UHFFFAOYSA-M tributyl(fluoro)stannane Chemical compound CCCC[Sn](F)(CCCC)CCCC DFNPRTKVCGZMMC-UHFFFAOYSA-M 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9914499A FR2801309B1 (fr) | 1999-11-18 | 1999-11-18 | Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20005807D0 NO20005807D0 (no) | 2000-11-17 |
| NO20005807L NO20005807L (no) | 2001-05-21 |
| NO318464B1 true NO318464B1 (no) | 2005-03-21 |
Family
ID=9552253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20005807A NO318464B1 (no) | 1999-11-18 | 2000-11-17 | Nye kamptotekinanaloge forbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6509345B2 (ja) |
| EP (1) | EP1101765B1 (ja) |
| JP (1) | JP3545332B2 (ja) |
| KR (1) | KR100460785B1 (ja) |
| CN (2) | CN1304395C (ja) |
| AT (1) | ATE222253T1 (ja) |
| AU (1) | AU772609B2 (ja) |
| BR (1) | BR0005486A (ja) |
| CA (1) | CA2325776C (ja) |
| DE (1) | DE60000328T2 (ja) |
| DK (1) | DK1101765T3 (ja) |
| EA (1) | EA003206B1 (ja) |
| ES (1) | ES2180501T3 (ja) |
| FR (1) | FR2801309B1 (ja) |
| HK (2) | HK1036803A1 (ja) |
| HU (1) | HUP0004573A3 (ja) |
| MX (1) | MXPA00011238A (ja) |
| NO (1) | NO318464B1 (ja) |
| NZ (1) | NZ508248A (ja) |
| PL (1) | PL202231B1 (ja) |
| PT (1) | PT1101765E (ja) |
| SI (1) | SI1101765T1 (ja) |
| ZA (1) | ZA200006730B (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2461572C (en) * | 2001-10-05 | 2011-02-15 | F. Hoffmann-La Roche Ag | Polycyclic compounds having anti-tumor activity |
| US7071204B2 (en) * | 2003-06-30 | 2006-07-04 | Research Triangle Institute | Camptothecin analogs having an E-ring ketone |
| FR2889527A1 (fr) * | 2005-08-05 | 2007-02-09 | Servier Lab | Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2889528B1 (fr) * | 2005-08-05 | 2007-09-07 | Servier Lab | Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2892418B1 (fr) * | 2005-10-24 | 2010-10-22 | Servier Lab | Nouveaux composes aminoesterifies a cycle e hydrocarbone a six chainons analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2892417B1 (fr) * | 2005-10-24 | 2010-10-22 | Servier Lab | Nouveaux composes aminoesterifies a cycle e hydrocarbone a sept chainons analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AU2007232206B2 (en) | 2006-03-30 | 2013-04-04 | Drais Pharmaceuticals, Inc. | Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same |
| CN103288842B (zh) * | 2012-02-24 | 2016-01-13 | 中国人民解放军第二军医大学 | 氟取代e环喜树碱类似物及其作为药物的用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5829793B2 (ja) * | 1975-02-07 | 1983-06-24 | 日本ケミフア （株） | ７−アルコキシカルボニル−８−メチルインドリジノ〔１，２−ｂ〕キノリン−９（１１Ｈ）−オンの製法 |
| JPS58435B2 (ja) * | 1975-12-23 | 1983-01-06 | カメタニ テツジ | ルテカルピンノセイホウ |
| GB8513460D0 (en) * | 1985-05-29 | 1985-07-03 | Glaxo Group Ltd | Chemical compounds |
| US4939255A (en) * | 1987-06-24 | 1990-07-03 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic camptothecin derivatives |
| US5004758A (en) * | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
| CA2102123A1 (en) * | 1991-07-22 | 1993-01-23 | Edwin M. Marker, Jr. | Reagent handling system for automated clinical analyzer apparatus |
| US5391745A (en) * | 1992-07-23 | 1995-02-21 | Sloan-Kettering Institute For Cancer Research | Methods of preparation of camptothecin analogs |
| ES2254600T3 (es) * | 1995-06-21 | 2006-06-16 | Societe De Conseils Et De Recherches D'applications Scientifiques (S.C.R.A.S.) | Nuevos analogos de la camptotecina, procedimientos de preparacion, su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. |
| UA57757C2 (uk) * | 1996-12-20 | 2003-07-15 | Сос'Єте Де Консей Де Решерш Е Даплікасьон С'Єнтіфік (С.К.Р.А.С.) | Аналоги камптотецину, спосіб їх отримання (варіанти) і фармацевтична композиція |
| DE19815812A1 (de) * | 1998-04-08 | 1999-10-14 | Bayer Ag | Modifizierte Cytostatika |
| US6043367A (en) * | 1998-09-30 | 2000-03-28 | Roffler; Steve | Proactive antitumor compounds |
-
1999
- 1999-11-18 FR FR9914499A patent/FR2801309B1/fr not_active Expired - Fee Related
-
2000
- 2000-11-09 PT PT00403108T patent/PT1101765E/pt unknown
- 2000-11-09 ES ES00403108T patent/ES2180501T3/es not_active Expired - Lifetime
- 2000-11-09 DE DE60000328T patent/DE60000328T2/de not_active Expired - Lifetime
- 2000-11-09 SI SI200030016T patent/SI1101765T1/xx unknown
- 2000-11-09 DK DK00403108T patent/DK1101765T3/da active
- 2000-11-09 AT AT00403108T patent/ATE222253T1/de active
- 2000-11-09 EP EP00403108A patent/EP1101765B1/fr not_active Expired - Lifetime
- 2000-11-15 MX MXPA00011238A patent/MXPA00011238A/es unknown
- 2000-11-16 JP JP2000348947A patent/JP3545332B2/ja not_active Expired - Fee Related
- 2000-11-17 CN CNB200410045949XA patent/CN1304395C/zh not_active Expired - Fee Related
- 2000-11-17 KR KR10-2000-0068441A patent/KR100460785B1/ko not_active IP Right Cessation
- 2000-11-17 NZ NZ508248A patent/NZ508248A/en not_active IP Right Cessation
- 2000-11-17 NO NO20005807A patent/NO318464B1/no not_active IP Right Cessation
- 2000-11-17 HU HU0004573A patent/HUP0004573A3/hu unknown
- 2000-11-17 EA EA200001084A patent/EA003206B1/ru not_active IP Right Cessation
- 2000-11-17 AU AU71683/00A patent/AU772609B2/en not_active Ceased
- 2000-11-17 CN CNB001284606A patent/CN1158282C/zh not_active Expired - Fee Related
- 2000-11-17 ZA ZA200006730A patent/ZA200006730B/xx unknown
- 2000-11-17 CA CA002325776A patent/CA2325776C/fr not_active Expired - Fee Related
- 2000-11-17 PL PL343949A patent/PL202231B1/pl not_active IP Right Cessation
- 2000-11-21 BR BR0005486-0A patent/BR0005486A/pt not_active IP Right Cessation
-
2001
- 2001-11-05 US US10/010,380 patent/US6509345B2/en not_active Expired - Fee Related
- 2001-11-07 HK HK01107780A patent/HK1036803A1/xx not_active IP Right Cessation
-
2005
- 2005-06-06 HK HK05104726A patent/HK1071892A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101876791B1 (ko) | 호흡기 세포융합 바이러스 항바이러스제로서의 아자인돌 | |
| JP2021504490A (ja) | 自己免疫疾患治療用ピラノピラゾールおよびピラゾロピリジン免疫調節薬 | |
| KR20100131475A (ko) | 살리노스포라마이드 ａ 및 그의 유사체들의 전합성 | |
| KR20080032007A (ko) | 신규의 캄토테신 유도체 화합물, 그들의 제조 방법 및 상기화합물을 포함하는 약제학적 조성물 | |
| Baxter et al. | Formal total synthesis of deserpidine demonstrating a versatile amino-Claisen rearrangement/Wenkert cyclization strategy for the preparation of functionalized yohimbane ring systems | |
| NO318464B1 (no) | Nye kamptotekinanaloge forbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
| CN101659668A (zh) | 制备喜树碱衍生物及其新中间体和化合物的方法 | |
| AU7168100A (en) | New 12,13-(pyranosyl)-indolo(2,3-a)pyrrolo(3,4-c)carbazole and 12,13-pyranosyl)-furo(3,4-c)indolo(2,3-a)carbazole compounds, a process for their preparation and pharmaceutical compositions containing them | |
| CA3130253A1 (en) | Cd73 inhibitor, preparation method therefor and application thereof | |
| Trabanco et al. | Synthesis of 2-N, N-dimethylaminomethyl-2, 3, 3a, 12b-tetrahydrodibenzo-[b, f] furo [2, 3-d] oxepin derivatives as potential anxiolytic agents | |
| US6699876B2 (en) | Camptothecin analogue compounds | |
| JP4308156B2 (ja) | 新規なベンゾ［ｂ］クロメノ−ナフチリジン−７−オン及びピラノ［２′，３′：７，８］キノ［２，３−ｂ］キノキサリン−７−オン化合物、それらの製法並びにそれらを含む医薬組成物 | |
| ES2334263T3 (es) | Nuevos compuestos analogos de la camptotecnica, su procedimiento de preparacion y composicion farmaceuticas que los contienen. | |
| JPH07101956A (ja) | ヒドロキシカンプトテシン化合物の製法 | |
| UA79997C2 (en) | Substituted compounds of [1,4] benzodioxine [2,3-e]izoindole, process for preparation thereof and pharmaceutical composition, which comprises them | |
| Kalshetti et al. | Stereoselective synthesis of subincanadine alkaloids framework | |
| ZA200502831B (en) | Substituded benzol {e} {1,4} oxazino {3,2-G} isoindole derivatives, method for preparing same and pharmaceutical compositions containing same | |
| Dumoulin et al. | Asymmetric synthesis of trans-3, 4-disubstituted tetrahydro-2-benzazepines | |
| JPH04117383A (ja) | ２―アルコキシカルボニル―２―メチル―１―オキソ―１，２，３，６，７，８―ヘキサヒドロ―ベンゾ〔１，２―ｂ；４，３―ｂ´〕ジピロール誘導体 | |
| Kim et al. | Preparation of (R)‐11‐hydroxyaporphine directly from (R)‐10, 11‐dihydroxyaporphine ((R)‐apomorphine) | |
| WO2006033011A1 (en) | Novel processes for the production of useful intermediates | |
| AU4117199A (en) | New 8H-thieno-(2,3-b)pyrrolizin-8-one compounds, a process for their preparation and pharmaceutical compositions containing them | |
| Suárez-Castillo et al. | DMD Mediated Formal Synthesis of (±)-Coerulescine | |
| Lillard | The thesis of John Sidney Mecom is approved |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |